风险提示：股市有风险，投资需谨慎。 来源:金融界 公司近期获得多项产品注册及变更，包括Ⅲ类医疗器械注册证有效期延长至2030年，注射泵、肠内营养 泵等新产品获批。子公司江西科伦医疗器械制造有限公司多项医疗器械注册证顺利延续。此外，公司还 获得"一种橡胶耐溶剂疲劳测试仪"的发明专利授权。 8月20日主力资金净流出3141.52万元，占流通市值0.49%。近五日主力资金累计净流出8672.13万元，占 流通市值1.36%。 中红医疗股价报16.28元，较前一交易日下跌0.68元，跌幅4.01%。开盘价为16.60元，最高触及16.76 元，最低下探至16.00元，成交量为17.95万手，成交金额2.93亿元。 中红医疗属于医疗器械行业，公司主要从事一次性健康防护手套、医用防护手套等产品的研发、生产和 销售。公司近期在海外市场布局取得进展，完成对东南亚SEA3公司75%股权的收购，并在东南亚投资 建设10条丁腈手套生产线。 ...

中红医疗（300981）公告，子公司深圳迈德瑞纳生物科技有限公司近期取得广东省药品监督管理局颁发 的《中华人民共和国医疗器械注册证》，注册类别为Ⅱ类。注册产品包括注射泵和输液信息采集系统， 注册证有效期至2030年7月16日。注射泵型号包括SP90、SP90Pro、SP90Neo，输液信息采集系统型号包 括DS80Pro、DS90Pro。 ...

中红医疗（300981）公告，子公司深圳迈德瑞纳生物科技有限公司近期取得了广东省药品监督管理局颁 发的《中华人民共和国医疗器械注册证》，迈德瑞纳申报的肠内营养泵、注射泵医疗器械注册证已审批 通过。 ...

Core Viewpoint - The stock price of Kangtai Medical has plummeted significantly since its IPO, leading to a drastic reduction in market capitalization and shareholder value, prompting the major shareholder to initiate a share reduction plan [1][2][8]. Group 1: Stock Performance and Market Capitalization - Kangtai Medical's market capitalization has dropped from over 120 billion yuan to approximately 5.46 billion yuan, representing a decline of 95.58%, which equates to a loss of about 117 billion yuan [2][7]. - The stock price reached a peak of 307.03 yuan per share at the time of listing but has since fallen to a historical low of 13.97 yuan per share [2][7]. Group 2: Financial Performance - Since 2021, Kangtai Medical has experienced a continuous decline in net profit for four consecutive years, with a reported loss of 77.9 million yuan in 2024 [3][9]. - The company's revenue has also decreased, with 2021 revenue at 909 million yuan, down 35.15% year-on-year, and subsequent years showing further declines [10][11]. - Despite the financial downturn, the company has maintained high dividend payouts, totaling approximately 392 million yuan from 2020 to 2023, with the major shareholder receiving around 230 million yuan [4][12][13]. Group 3: Shareholder Actions - On May 8, 2024, the controlling shareholder, Hu Kun, announced plans to reduce his holdings by up to 12 million shares, which could yield approximately 168 million yuan [6][7]. - This marks Hu Kun's first instance of cashing out since the company's IPO, amidst a trend of frequent share reductions by executives and shareholders since 2021 [8]. Group 4: Product Quality and Legal Issues - In 2024, Kangtai Medical faced scrutiny over product quality, with several products failing to meet standards, resulting in a fine of 30,000 yuan [16][17]. - The company was also involved in a patent infringement lawsuit with Beijing Chao Si Electronic Technology, which was settled in December 2024 for 1 million USD [19][20][21].